GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (FRA:I4AA) » Definitions » Cyclically Adjusted Price-to-FCF

IntelliPharmaCeutics International (FRA:I4AA) Cyclically Adjusted Price-to-FCF : (As of Jun. 20, 2024)


View and export this data going back to 2013. Start your Free Trial

What is IntelliPharmaCeutics International Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


IntelliPharmaCeutics International Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Cyclically Adjusted Price-to-FCF Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF falls into.



IntelliPharmaCeutics International Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

IntelliPharmaCeutics International's Cyclically Adjusted FCF per Share for the quarter that ended in Aug. 2023 is calculated as:

For example, IntelliPharmaCeutics International's adjusted Free Cash Flow per Share data for the three months ended in Aug. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Aug. 2023 (Change)*Current CPI (Aug. 2023)
=0.007/125.3885*125.3885
=0.007

Current CPI (Aug. 2023) = 125.3885.

IntelliPharmaCeutics International Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201311 -0.681 97.182 -0.879
201402 0.047 98.051 0.060
201405 0.220 99.394 0.278
201408 -0.554 99.315 -0.699
201411 -0.555 99.078 -0.702
201502 -0.060 99.078 -0.076
201505 -0.495 100.263 -0.619
201508 -0.516 100.579 -0.643
201511 -0.524 100.421 -0.654
201602 -0.677 100.421 -0.845
201605 -0.481 101.765 -0.593
201608 -1.230 101.686 -1.517
201611 0.110 101.607 0.136
201702 -0.765 102.476 -0.936
201705 -0.521 103.108 -0.634
201708 -0.458 103.108 -0.557
201711 -0.536 103.740 -0.648
201802 -0.380 104.688 -0.455
201805 -0.073 105.399 -0.087
201808 -0.259 106.031 -0.306
201811 -0.762 105.478 -0.906
201902 -0.156 106.268 -0.184
201905 -0.076 107.927 -0.088
201908 -0.045 108.085 -0.052
201911 -0.010 107.769 -0.012
202002 -0.002 108.559 -0.002
202005 0.003 107.532 0.003
202008 0.024 108.243 0.028
202011 -0.022 108.796 -0.025
202102 0.000 109.745 0.000
202105 -0.023 111.404 -0.026
202108 -0.035 112.668 -0.039
202111 -0.009 113.932 -0.010
202202 -0.015 115.986 -0.016
202205 -0.010 120.016 -0.010
202208 -0.009 120.569 -0.009
202211 -0.004 121.675 -0.004
202302 0.000 122.070 0.000
202305 0.003 124.045 0.003
202308 0.007 125.389 0.007

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IntelliPharmaCeutics International  (FRA:I4AA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


IntelliPharmaCeutics International Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (FRA:I4AA) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (FRA:I4AA) Headlines

No Headlines